You are here
Report: First Class of Biosimilars to Enter U.S. Market Could Generate $1.8 Billion in Sales by 2023
Decision Resources Group, a health care research firm located in Burlington, Mass., reports that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim, which is currently pending FDA approval, and pegfilgrastim could reach $1.8 billion in the U.S. by 2023.
Medical oncologists and hematologist-oncologists surveyed in France and Germany indicated that they would prescribe future biosimilar G-CSFs, such as pegfilgrastim, to a significantly higher percentage of eligible patients compared with biosimilars of monoclonal antibodies (MAbs). In addition, a greater proportion of surveyed oncologists indicated that they expected to start prescribing biosimilar G-CSFs within 6 months of availability compared with biosimilar MAbs.
“Filgrastim biosimilars have performed well in Europe, with sales exceeding the reference product in many countries. Now those biosimilars are on the verge of entering the U.S. market, where we expect U.S. oncologists to swiftly adopt these tried-and-tested lower-cost alternatives to Amgen’s Neupogen [filgrastim],” said analyst Kate Keeping.
Most of the surveyed oncologists indicated that they have a preferred biosimilar filgrastim product, and that their preference is driven by which manufacturer they trust most.
The proportion of surveyed oncologists that indicated that regulatory approval would not allay all of their concerns about equivalence between a biosimilar and the reference brand was higher for MAbs than for G-CSFs.
“Surveyed oncologists’ responses indicated that they view the use of biosimilars differently in a therapeutic setting, compared with a supportive-care setting,” Keeping said.
Source: BioTrends Research Group; November 19, 2014.